Key regions: Japan, India, Italy, Brazil, South Korea
The demand for Anti-Hypertensive Drugs in Kazakhstan has been steadily increasing in recent years.
Customer preferences: Kazakhstan has a large population of middle-aged and elderly people who are more susceptible to hypertension. As a result, there has been a growing demand for Anti-Hypertensive Drugs in the country. Additionally, due to the high prevalence of hypertension in the region, there is a greater awareness among the general public about the importance of managing the condition, leading to an increase in demand for these drugs.
Trends in the market: The Anti-Hypertensive Drugs market in Kazakhstan is dominated by international pharmaceutical companies. However, there has been a recent trend of local pharmaceutical companies entering the market, which has led to increased competition. This has resulted in a decrease in the prices of these drugs, making them more accessible to the general public. Additionally, there has been a shift towards generic drugs, which are more affordable and have the same efficacy as branded drugs.
Local special circumstances: Kazakhstan has a state-run healthcare system, which provides free medical care to its citizens. However, due to the limited resources of the system, there is often a shortage of drugs in public hospitals and clinics. As a result, many people opt to purchase their medication from private pharmacies. This has led to the growth of private pharmacies in the country, which has further fueled the demand for Anti-Hypertensive Drugs.
Underlying macroeconomic factors: The Kazakh economy has been growing steadily in recent years, which has led to an increase in disposable income among the population. This has resulted in a greater ability to afford medication, leading to an increase in demand for Anti-Hypertensive Drugs. Additionally, the government has been investing heavily in the healthcare sector, which has led to an improvement in the quality of medical care in the country. This has further fueled the demand for these drugs as people have greater access to medical care and are more aware of the importance of managing hypertension.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
